The National Institutes of Health, through its NIH Guide, has recently published the following funding-related notices and funding opportunities:

Policy Notices

• NIH Enforcement of Unilateral Closeout Reporting in the System for Award Management Responsibility/Qualification (formerly Federal Awardee Performance and Integrity Information System (FAPIIS)
  (NOT-OD-24-055)
  National Institutes of Health

General Notices

• Notice of Intent to Publish a Multi-Agency initiative in support of Establishment of an Industry-University Cooperative Research Center (IUCRC) on Optical Imaging Phantom Development and Dissemination
  (NOT-EB-24-004)
  National Institute of Biomedical Imaging and Bioengineering

• NHLBI Announces Plan to Fund a Framingham Heart Study Exam for the Generation 2 and Omni 1 Cohorts
  (NOT-HL-24-001)
  National Heart, Lung, and Blood Institute

• Notice of NHLBI Participation in PAR-22-151 Fogarty HIV Research Training Program for Low-and Middle-Income Country Institutions (D43 Clinical Trial Optional)
  (NOT-HL-24-073)
  National Heart, Lung, and Blood Institute

• NIH Blueprint for Neuroscience Research: Request for Information (RFI) on the NIH Toolbox Assessments Conference
  (NOT-AG-23-076)
  National Institute on Aging
  National Center for Complementary and Integrative Health
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Biomedical Imaging and Bioengineering
  Eunice Kennedy Shriver National Institute of Child Health and Human Development
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of Behavioral and Social Sciences Research

Notice of Changes to Funding Opportunities

• Notice of Need to Expire and Reissue NOT-AT-22-010 "Notice of Special Interest (NOSI): Administrative Supplements for Complementary Health Practitioner Research Experience (Admin Supplements)" to Change Due Dates
  (NOT-AT-24-029)
  National Center for Complementary and Integrative Health

• Notice of Need to Expire and Reissue NOT-AT-24-012 "Notice of Special Interest: National Center for Complementary and Integrative Health (NCCIH) T32 Supplement Program to Promote Diversity in Health Research" to Change Due Dates
  (NOT-AT-24-031)
  National Center for Complementary and Integrative Health

• Notice of Extension of the Expiration Date for PAR-21-166 "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Not Allowed)"
  (NOT-CA-24-025)
  National Cancer Institute

• Notice of Extension of the Expiration Date for PAR-21- 206 "Academic-Industrial Partnerships for Translation of Technologies for Diagnosis and Treatment (R01 - Clinical Trial Optional)"
  (NOT-CA-24-026)
  National Cancer Institute

• Notice of NCIs Participation in PAR-23-319, Implementation Research on Noncommunicable Disease Risk Factors among Low- and Middle-Income Country and Tribal Populations Living in City Environments (R01 Clinical Trial Optional)
  (NOT-CA-24-027)
  National Cancer Institute

• Notice of Change to Extend Last Receipt Date and the Expiration Date for PAR-21-187 and PAR- 21-188
  (NOT-DC-24-021)
  National Institute on Deafness and Other Communication Disorders

• Notice of Change to Funding Opportunity: RFA-FD-24-029 Collaborations to Enhance Drug Development and Regulatory Science - Clinical Trials Optional
  (NOT-FD-24-001)
  Food and Drug Administration

• Notice of Change to Funding Opportunity: RFA-FD-24-025 Cooperative Agreement to Support a Human Abuse Potential Study of Botanical Kratom (U01 Clinical Trial Required)
  (NOT-FD-24-002)
  Food and Drug Administration

• Notice of Change to Funding Opportunity: RFA-FD-24-029 Collaborations to Enhance Drug Development and Regulatory Science - Clinical Trials Optional
  (NOT-FD-24-003)
  Food and Drug Administration

• Notice of Change to Receipt Dates for RFA-NS-24-013: Efficacy and Safety of Amyloid-Beta Directed Antibody Therapy in Mild Cognitive Impairment and Dementia with Evidence of Both Amyloid-Beta and Vascular Pathology (U01 - Clinical Trial Required)
  (NOT-NS-24-044)
  National Institute of Neurological Disorders and Stroke

• Notice of Early Termination of PAR-24-078: Limited Competition: Specific Pathogen Free Macaque Colonies (U42 Clinical Trial Not Allowed)
  (NOT-OD-24-056)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs

Notices of Intent to Publish

• Notice of Intent to Publish a Notice of Funding Opportunity for Diabetes Research Centers (P30 Clinical Trial Optional)
  (NOT-DK-24-009)
  National Institute of Diabetes and Digestive and Kidney Diseases

Notices of Special Interest

• Notice of Special Interest: Administrative Supplements for Complementary Health Practitioner Research Experience (Admin Supplements)
  (NOT-AT-24-032)
  National Center for Complementary and Integrative Health

Funding Opportunities

• Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders(U01 Clinical Trial Optional)
  (PAR-24-095)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
   
• Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
  (PAR-24-096)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
   
• Clinical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U01 Clinical Trial Optional)
  (PAR-24-097)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
   
• Analytical Validation of a Candidate Biomarker for Neurological or Neuromuscular Disorders (U44 Clinical Trial Optional)
  (PAR-24-098)
  National Institute of Neurological Disorders and Stroke
  Application Receipt Date(s): Multiple dates, see announcement.
  
   
• Understanding Mechanisms and Outcomes of Trained Immunity (R21 Clinical Trial Not Allowed)
  (PAR-24-111)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): January 07, 2027
  
   
• Understanding Mechanisms and Outcomes of Trained Immunity (R01 Clinical Trial Not Allowed)
  (PAR-24-112)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): January 07, 2027
  
   
• International Research Scientist Development Award (IRSDA) (K01) Independent Clinical Trial Not Allowed
  (PAR-24-113)
  John E. Fogarty International Center
  National Cancer Institute
  National Institute on Deafness and Other Communication Disorders
  Application Receipt Date(s): Multiple dates, see announcement.
  
   
• Limited Competition: Specific Pathogen Free Macaque Colonies to Support HIV/AIDS Research (U42 Clinical Trial Not Allowed)
  (PAR-24-129)
  Division of Program Coordination, Planning and Strategic Initiatives, Office of Research Infrastructure Programs
  Office of AIDS Research
  Application Receipt Date(s): Not Applicable
  
   
• Novel Approaches for Radiation Biodosimetry Assays and Devices Development (U01 Clinical Trial Not Allowed)
  (RFA-AI-24-003)
  National Institute of Allergy and Infectious Diseases
  Application Receipt Date(s): May 31, 2024
  
   
• Novel Approaches to Support Therapeutic Development in Ultra-Rare Cancers (U01) Clinical Trial Optional
  (RFA-FD-24-019)
  Food and Drug Administration
  Application Receipt Date(s): March 25, 2024 by 11:59 PM Eastern Time. Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. Applicants should be aware that on-time submission means that an application is submitted error free (of both Grants.gov and eRA Commons errors) by 11:59 PM Eastern Time on the application due date. Late applications will not be accepted for this FOA.
  
   
• Flexible Funding Model-Infrastructure Development and Maintenance for State Manufactured Food Regulatory Programs (UM1) Clinical Trials Not Allowed
  (RFA-FD-24-021)
  Food and Drug Administration
  Application Receipt Date(s): April 01, 2024
  
   
• Development and Maintenance of Human and Animal Food Rapid Response Teams (U01) Clinical Trials Not Allowed
  (RFA-FD-24-032)
  Food and Drug Administration
  Application Receipt Date(s): April 01, 2024
  
   
• Evaluation and Coordinating Center for the AHRQ/PCORI Learning Health System Embedded Scientist Training and Research Centers (U18)
  (RFA-HS-24-002)
  Agency for Healthcare Research and Quality
  Application Receipt Date(s): March 30, 2024
  
   
• Transformative Research to Address Health Disparities and Advance Health Equity (U01 Clinical Trial Optional)
  (RFA-NR-24-004)
  National Institute of Nursing Research
  National Center for Complementary and Integrative Health
  National Heart, Lung, and Blood Institute
  National Institute on Aging
  National Institute on Alcohol Abuse and Alcoholism
  National Institute of Arthritis and Musculoskeletal and Skin Diseases
  National Institute on Drug Abuse
  National Institute of Dental and Craniofacial Research
  National Institute of Environmental Health Sciences
  National Institute of Mental Health
  National Institute of Neurological Disorders and Stroke
  Office of Behavioral and Social Sciences Research
  Office of Disease Prevention
  Office of Research on Women's Health
  Application Receipt Date(s): March 22, 2024

Members of the University of Iowa community may direct questions to the UI Division of Sponsored Programs at dsp@uiowa.edu or 313-335-2123, or email Ann Ricketts or Lynn Hudachek.